ACTIV-3 will test therapeutics in volunteers with more severe cases of COVID-19.

Tuesday, August 4, 2020 NIH Launches Clinical Trial to Test Antibody Treatment in Hospitalized COVID-19 Patients NIAID is supporting a set of adaptive treatment studies for COVID-19. The trial called ACTIV-3 will test therapeutics in volunteers with more severe cases of COVID-19. At first, these hospitalized volunteers will receive an experimental monoclonal antibody treatment in addition to the standard of care. This trial may also be expanded to test additional therapeutics later. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107